Recent New Videos Posting

COVID Vaccinations for Transplantation


Open to all healthcare professionals / Donors / Recipients / Families

Steven Chadban, Paul Harden, Camille Kotton, Michael Ison, Ligia Pierotti


April 13, 2021

Open to all healthcare professionals


TID Council - We are mourning the loss of a dear friend and leader

Francisco Marty

It is with great sadness that we note the death of TID Executive Committee member Francisco Marty on April 8, 2021 from a fall while photographing a waterfall in the Dominican Republic.  Francisco is recognized globally for his expertise in treating transplant and cancer patients.  He was a dedicated clinician, patient advocate, and teacher, taking extraordinary joy in mentoring new generations of clinicians. He was an incredibly generous mentor, who continued to help his many trainees and colleagues throughout the world long after their official relationship had ended.   In addition to his accomplishments related to the diagnosis, prevention, and treatment of fungal and viral diseases in immunocompromised hosts, Francisco was a talented photographer, touching the lives of others with stunning images that showcased the same passion he applied to his patients and research ( A dedicated member of the scientific community, he served as a co-editor-in-chief of TID since 2011, guiding the growth of the journal, which has now become the flagship journal for transplant infectious diseases. He was recognized as someone who not only directly contributed to the medical literature through his impactful clinical trials and epidemiologic investigations but also his ability to analyze existing literature and break it down so that it was easily understandable.  He gave talks on every corner of the globe and was well recognized as a Transplant ID Twitter influencer.  He will be remembered fondly for his wisdom, kindness and enormous generosity. The TID Section extends its deepest condolences to his friends and family, and its gratitude for his commitment to the fields and all members of the TID community.  Our field has lost one of the giants who will be missed by the field and all who knew him.

Journal Updates

Upcoming Webinar

Highlighted News

Researchers develop a technique to produce transplantable livers in the laboratory

Extracellular matrix of a decellularized liver - CREDIT: HUG-CELL/USP
April 5 - Researchers at the Human Genome and Stem Cell Research Center (HUG-CELL), hosted by the University of São Paulo's Institute of Biosciences (IB-USP) in Brazil, have developed a technique to reconstruct and produce livers in the laboratory. The proof-of-concept study was conducted with rat livers. In the next stage of their research, the scientists will adapt the technique for the production of human livers in order in future to increase the supply of these organs for transplantation.

Japanese doctors perform world's first living donor lung transplant to a Covid-19 patient

April 9 - A Japanese woman whose lungs were severely damaged by Covid-19 has received what doctors say is the world's first lung transplant from living donors to a recovered coronavirus patient.

Building Confidence in COVID-19 Vaccines

April 15 - Recent virtual forum titled “Building Vaccine Confidence: Best Practices to Combat Misinformation and Vaccine Hesitancy in COVID-19 Vaccines.” The forum took place during the American Association for Cancer Research’s Annual Meeting 2021, which had more than 13,500 registrants. This screenshot shows the panel getting ready for our informative discussion on building confidence in the COVID-19 vaccines. The forum took place on April 14, 2021.

Researchers Devise Rapid 3D Printing Method for Human Organs

April 6 - The Holy Grail of 3D bioprinting is to one day be able to fabricate full-sized human organs and tissues to replace the real thing in cases of transplant surgeries and other biomedical applications. Researchers at the University at Buffalo have made a significant step not only to achieve this endeavor but to do it quickly. A team of researchers there has developed 3D-printing technology that has demonstrated rapid printing of life-sized organs and limbs such as a human hand in less than 20 minutes.

Hot off the Press 


Selected Publications by TTS Education Committee. This week's selection made by Enver Akalin and Marlies Reinders..

Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients

Arne Sattler et al.
This study analyzed humoral and cellular responses in kidney transplant recipients after prime-boost vaccination with BNT162b2. As opposed to all healthy vaccinees and the majority of hemodialysis patients, only 4/39 and 1/39 transplanted individuals showed IgA and IgG seroconversion at day 8±1 after booster immunization with minor changes until day 23±5, respectively. Although most transplanted patients mounted spike specific T helper cell responses, frequencies were significantly reduced compared to controls and dialysis patients, accompanied by a broad impairment in effector cytokine production, memory differentiation and activation-related signatures. Spike-specific CD8+ T cell responses were less abundant than their CD4+ counterparts in healthy controls and hemodialysis patients and almost undetectable in transplant patients. Signs of alloreactivity promoted by BNT162b2 were not documented within the observation period.

Changes in Humoral Immune Response after SARS-CoV-2 Infection in Liver Transplant Recipients Compared to Immunocompetent Patients

Aránzazu Caballero-Marcos et al.
Am J Transplant. 2021 Apr 9.doi: 10.1111/ajt.16599.
A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p< 0.001) and at 6 months (63.4% vs. 90.1%, p<0.001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p=0.001) and 6 months (p<0.001) after COVID-19. In transplant patients, female gender (OR=13.49, 95%CI 2.17-83.8), a longer interval since transplantation (OR=1.19, 95%CI 1.03-1.36), and therapy with renin–angiotensin– aldosterone system inhibitors (OR=7.11, 95%CI 1.47-34.50) were independently associated with persistence of antibodies beyond 6 months after COVID-19.



Staff Directory


The Transplantation Society
International Headquarters
740 Notre-Dame Ouest
Suite 1245
Montréal, QC, H3C 3X6